JAK1 Inhibitors Show Superior Antipruritic Effects Over IL-13 Antibodies in Atopic Dermatitis
核心洞察
JAK1 inhibitors (搜索) demonstrated superior antipruritic efficacy compared to IL-13 antibodies (搜索) in 75 patients with moderate-to-severe atopic dermatitis (搜索), with 100% of JAK1 (搜索)-treated patients showing improvement in pruritus scores versus 60% in the IL-13 (搜索) group.
Patients receiving JAK1 inhibitors (搜索) were 9 times more likely to achieve clinically meaningful pruritus reduction and 34 times more likely to reach near-complete itch relief compared to those treated with IL-13 antibodies (搜索).
Both treatment classes showed similar safety profiles with comparable adverse event rates, though JAK1 inhibitors (搜索) were associated with faster early responses while biologics (搜索) provided greater long-term improvements.
A head-to-head comparison of JAK1 inhibitors (搜索) and IL-13 antibodies (搜索) in moderate-to-severe atopic dermatitis (搜索) has revealed significant differences in antipruritic efficacy, with JAK1 inhibitors demonstrating superior itch control as early as three months after treatment initiation. The retrospective analysis of 75 patients at Fukuoka University Hospital in Japan provides the first direct comparison of these two therapeutic approaches using pathway-specific biomarkers.
Superior Pruritus Control with JAK1 Inhibitors
The study showed striking differences in pruritus management between the two treatment classes. All patients (100%) in the JAK1 (搜索) inhibitor group demonstrated improvement in Peak Pruritus Numerical Rating Scale (PP-NRS) scores at three months, compared to only 60% of patients receiving IL-13 antibodies (搜索) (P < 0.0001). Final PP-NRS scores were significantly lower in the JAK1 group (0 vs 2, P = 0.0003).
Multivariate logistic regression analysis identified JAK1 inhibitors (搜索) as independent predictors for achieving two critical pruritus milestones. Patients were 9.36 times more likely to achieve PP-NRS ≤4 (odds ratio 9.36, 95% CI 1.88-46.52, P = 0.0063), with 30% of JAK1 (搜索)-treated patients reaching this threshold versus 17% in the IL-13 (搜索) group. Even more remarkably, JAK1 inhibitor patients were 34.61 times more likely to achieve near-complete itch relief (PP-NRS 0/1) compared to IL-13 antibody recipients (odds ratio 34.61, 95% CI 5.93-202.04, P < 0.0001), with 27% versus 8% reaching this milestone.
Comparable Efficacy in Overall Disease Control
While JAK1 inhibitors (搜索) excelled in pruritus management, both treatment classes showed similar efficacy in overall disease control. EASI score improvements were observed in 83.33% of JAK1 (搜索) inhibitor patients versus 79.98% of IL-13 (搜索) antibody patients (P = 0.4280), indicating comparable effectiveness in reducing skin inflammation and lesion severity.
Distinct Patient Populations and Biomarker Profiles
The study revealed important baseline differences between treatment groups that may influence therapeutic selection. JAK1 (搜索) inhibitor patients were significantly younger (median 38 years vs 57 years, P = 0.0054) and presented with more severe disease, including higher baseline EASI scores (26.5 vs 18.7, P = 0.0019) and elevated inflammatory markers. These patients had higher baseline eosinophil counts, serum IgE levels (4071 vs 1585, P = 0.0271), and TARC (搜索) levels (2949 vs 1901, P = 0.0142).
Biomarker responses also differed between groups. JAK1 (搜索) inhibitor treatment led to eosinophil count improvements in 56.83% of patients, while 25.92% experienced worsening (P < 0.0001). Conversely, IL-13 antibodies (搜索) showed potential benefits in TARC (搜索) level improvements, with 55.01% of patients showing improvement versus 37.22% in the JAK1 group (P = 0.1667).
Safety Profiles and Real-World Effectiveness
Both treatment classes demonstrated acceptable safety profiles with similar overall adverse event rates: 45.95% for JAK1 inhibitors (搜索) versus 39.47% for IL-13 antibodies (搜索) (P = 0.6438). Reported adverse events included acne or folliculitis, viral warts, herpes zoster, ocular symptoms, fatigue, asthma exacerbation, and grade 3 eosinophilia, with severe adverse events being rare in both groups.
Real-world data from a separate Spanish study of 202 patients corroborated these findings, showing that JAK inhibitors (搜索) demonstrated faster early responses while biologics (搜索) led to greater absolute improvements between weeks 16 and 52 with longer treatment persistence. The adverse event profiles differed between drug families, with infections and acne more common with JAK inhibitors, while ocular symptoms were more frequent with biologics.
Clinical Implications for Treatment Selection
The research provides crucial insights for personalizing atopic dermatitis (搜索) treatment strategies. The superior antipruritic effects of JAK1 inhibitors (搜索) make them particularly valuable for patients where itch control is the primary concern, especially given that pruritus often represents the most debilitating symptom for patients with moderate-to-severe atopic dermatitis.
The identification of baseline biomarkers as predictors of treatment response offers potential for precision medicine approaches. Baseline EASI score, TARC (搜索) improvement rate, and IgE improvement rate emerged as significant predictors of EASI-75 achievement, while positive correlations were observed between eosinophil improvement rates and overall clinical improvements in JAK1 (搜索) inhibitor patients.
The study authors noted that their findings represent "the first direct comparison of selective JAK1 inhibitors (搜索) and IL-13 antibodies (搜索), with a focus on pathway-specific biomarkers," providing novel insights into personalized therapeutic strategies. However, they acknowledged limitations including the retrospective design, small sample size, short follow-up period, and potential residual confounding from different prescribing patterns in clinical practice, emphasizing the need for larger prospective studies with longer follow-up periods to validate these findings and establish long-term treatment algorithms.